Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 2.2% - Time to Sell?

Key Points

• Greenwich LifeSciences shares experienced a decline of 2.2% in trading, reaching a low of $9.17, with a recent market cap of $126.49 million.
• Analysts have mixed opinions on the stock, with a consensus rating of “Hold” and a target price of $42.00, while Weiss Ratings issued a "sell (e+)" recommendation.
• The company reported an earnings miss for the last quarter, with an EPS of ($0.30), lower than the consensus estimate of ($0.24).

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report)'s stock price traded down 2.2% during trading on Monday . The company traded as low as $9.17 and last traded at $9.28. 71,976 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 75,976 shares. The stock had previously closed at $9.49.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Noble Financial assumed coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They issued an "outperform" rating and a $45.00 price target for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Greenwich LifeSciences in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $42.00.

Greenwich LifeSciences Price Performance

The stock's fifty day simple moving average is $11.15 and its 200-day simple moving average is $10.42. The stock has a market cap of $126.49 million, a P/E ratio of -6.82 and a beta of 1.62.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.06). Analysts forecast that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.

Hedge Funds Weigh In On Greenwich LifeSciences

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC bought a new stake in shares of Greenwich LifeSciences during the first quarter valued at approximately $126,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Greenwich LifeSciences during the second quarter valued at approximately $25,000. Bank of America Corp DE raised its holdings in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after buying an additional 1,322 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after buying an additional 3,168 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Greenwich LifeSciences during the first quarter valued at approximately $147,000. Institutional investors own 4.16% of the company's stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.